Prot #27918: A phase III, Double-Blind, Placebo-Controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/day) and High (100 mg/day) Dose of Safinamide, as Add-on Therapy, in Subjects with Early Idiopathic Parkinson's Disease Treate

Project: Research project

Project Details

StatusFinished
Effective start/end date3/9/10 → 3/9/13

Funding

  • Quintiles, Inc. (Prot # 27918 // Prot # 27918)
  • EMD Serono, Inc. (Prot # 27918 // Prot # 27918)